The latest price target for Nurix Therapeutics (NASDAQ:NRIX) was reported by Stephens & Co. on January 21, 2025. The analyst firm set a price target for $31.00 expecting NRIX to rise to within 12 months (a possible 58.16% upside). 41 analyst firms have reported ratings in the last year.

The latest analyst rating for Nurix Therapeutics (NASDAQ:NRIX) was provided by Stephens & Co., and Nurix Therapeutics reiterated their overweight rating.

The last upgrade for Nurix Therapeutics Inc happened on May 31, 2022 when Wells Fargo raised their price target to $25. Wells Fargo previously had an equal-weight for Nurix Therapeutics Inc.

There is no last downgrade for Nurix Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nurix Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nurix Therapeutics was filed on January 21, 2025 so you should expect the next rating to be made available sometime around January 21, 2026.

While ratings are subjective and will change, the latest Nurix Therapeutics (NRIX) rating was a reiterated with a price target of $31.00 to $31.00. The current price Nurix Therapeutics (NRIX) is trading at is $19.60, which is out of the analyst’s predicted range.